Eli Lilly and Co (LLY) — Q1 FY26 Earnings Call Live coverage with Benzinga. Q1 FY26 Results EPS: $8.55 (est. $6.85) — inline Revenue: $19.80B (est. $17.78B) — inline Reported: 2026-04-30 Recent Quarters Q4 FY25 (2026-02-04): EPS $7.54 vs est $6.96 · Rev $19.30B vs est $17.91B Q3 FY25 (2025-10-30): EPS $7.02 vs est $5.96 · Rev $17.60B vs est $16.05B Q2 FY25 (2025-08-07): EPS $6.31 vs est $5.60 · Rev $15.56B vs est $14.70B Q1 FY25 (2025-05-01): EPS $3.34 vs est $3.02 · Rev $12.73B vs est $12.66B About Eli Lilly and Co Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. lilly.com · Indianapolis, IN, USA · 50,000 employees Follow Benzinga X: x.com/Benzinga Facebook: facebook.com/Benzinga Instagram: instagram.com/benzinga ⚠️ D...